The Importance of Timeliness in Outbreak Response: Introducing the WHO’s Early Action Review

By Staff Writer

September 5, 2023

The recent outbreaks of epidemic and pandemic-prone diseases have underscored the importance of timely and effective systems for outbreak detection, notification, and response. Early detection and response are crucial in preventing the escalation of outbreaks of infectious disease. To enhance the identification and control of these threats, ambitious and achievable targets are required.

In response to this need, the World Health Organization (WHO) has developed the Early Action Review (EAR), a performance improvement approach used to evaluate the timeliness of early detection activities and responses to any health event. The EAR, when repeated consistently, establishes the habit of ensuring continual learning and improvement from every event.

EAR is not just an assessment or monitoring tool: it’s a performance management process conducted as early as possible while an event is unfolding. It is used by teams responsible for responding to the event to reinforce the implementation of seven early response actions. These include initiating investigations, conducting epidemiologic analysis, obtaining laboratory confirmation, initiating appropriate case management and infection prevention measures, and establishing a coordination mechanism.


EAR also promotes collaboration and coordination among key stakeholders during the early outbreak response, increasing the likelihood of effective control. When a new outbreak or public health event is identified, stakeholders must coordinate efforts to control the spread of disease and reduce risks or impacts.

The EAR process is designed to find system bottlenecks and fix them quickly. Stakeholders in a response capture data about the timeliness and completion of early response actions as the event unfolds and then identify bottlenecks in the system and enablers of implementation. Documenting these bottlenecks and enablers is critical for prioritising immediate or longer-term remedial actions and identifying best practices.

The WHO has made available five tools to support the conduct of an EAR, which can be downloaded from their website. These tools will be periodically updated, as required. By implementing and improving the EAR process, countries can enhance both their detection speed and response quality, ultimately saving lives and preventing the spread of infectious diseases. 

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.